<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230226057539N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-20</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of macular detachment surgery with ILM flap in retinal hole treatment</public_title>
      <acronym></acronym>
      <scientific_title>Efficacy of Combined Internal Limiting Membrane Peeling and Macular Detachment surgery compared to Internal Limiting Membrane Peeling and Flap surgery in the treatment of Large macular hole in Isfahan city in 2023</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-03-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69068</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Based on the method of random allocation (randomization software of Dr. Soqaei), the patients were divided into two groups of 15 patients using the first surgical method, macular detachment (MD) or the second surgical method (Internal limiting membrane peeling with inverted flap). By ensuring the randomness of the treatment allocation, this software reduces the interactive effect of unknown factors and helps to examine the effect of the treatment more accurately. First, we enter the details of the plan include the number of groups (2 groups), the number of participants in each group (15 patients) and the type of the treatment (first or second surgical method) into the software. Then, using the random assignment option, numeric and random codes are given in the software, and the software randomly divides the patients into the first or second surgical groups, and the surgeon selects the surgical method using the obtained information. The software link is below:
https://drive.google.com/file/d/0B9juB1UY-iu4TzZUVzZLOVZvM0k/view?usp=sharing, Blinding description: Patients will be informed about the two surgical procedures, but will not be informed about which surgical procedure will be used for them. Based on randomization with the help of the software, the surgeon will be obliged to perform the surgery for the patient based on the scientific principles of surgery without having the right to choose the surgical method for the patient. Finally, the examination will be continued by the researcher.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Macular hole.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  combined Macular detachment and Internal Limiting Membrane peeling surgery                                                                                     1. Deep vitrectomy is performed in the standard way with 3 ports.2. If the posterior hyaloid is not detached, posterior vitreous detachment is induced.3. ILM staining is done with the help of Brilliant Blue, and after 1 to 2 minutes, ILM peeling is done in the macular area in a circular manner in the vascular area.4. BSS injection is done through a 25/38 gauge cannula which is connected to a syringe containing BSS. These injections are done in 4 quadrants. The injection continues until the retinal bleb reaches the edge of the macular hole and can be seen exiting through the hole.5. Finally, air-fluid exchange is performed and internal tamponade is performed with the help of undiluted C3F8 gas in the amount of 0.4 ml inside the vitreous, and the patient is asked to sleep with face down position. Intervention 2: Control group: Internal Limiting Membrane peeling and inverted flap . 1. Deep vitrectomy is performed.2. ILM staining is performed, ILM peeling is performed in the macular area in a circular manner in the vascular area.3. The removed ILM is placed as a flap inside the macular hole.4. Finally, air-fluid exchange is performed and internal tamponade is performed with the help of undiluted C3F8 gas, and the patient is asked to lie with face down position.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only part of the data related to the main outcome will be shared.

When:
Access will start after the completion of the study and at the time of submitting the study to scientific journals.

To whom:
Only researchers working in academic and scientific institutions

Conditions:
Data analysis will be possible only after obtaining permission from the authors and researchers.

Where to obtain:
Responsible author or scientific responsible for the study with the help of the email

How to obtain:
After requesting the data, the researchers will work together to send the data information to the requester within one month.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Khodayar Golabchigilani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Feiz Hospital, Qods Sq, Esfahan</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4487481496</zip>
        <telephone>+98 31 3445 2031</telephone>
        <email>khodayar82@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Khodayar Golabchigilani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Feiz Hospital, Qods Sq, Isfahan City</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4487481496</zip>
        <telephone>+98 31 3447 6012</telephone>
        <email>khodayar82@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Macular hole greater than 400 microns based on clinical examination and Spectral Domain Optical Coherence Tomography (SD-OCT)
Macular hole (MH) in which the patient's symptoms have lasted less than 2 years
Age above 50 years</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Perform any retinal surgery or retinal laser
Retinal holes due to secondary causes such as trauma
Stage 1 or 2 macular holes
Any disease other than Macular Hole (MH) that affects visual acuity except cataract
If, for any reason, silicone oil is injected for tamponade during surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H35.34</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Macular cyst, hole, or pseudohole</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  combined Macular detachment and Internal Limiting Membrane peeling surgery                                                                                     1. Deep vitrectomy is performed in the standard way with 3 ports.2. If the posterior hyaloid is not detached, posterior vitreous detachment is induced.3. ILM staining is done with the help of Brilliant Blue, and after 1 to 2 minutes, ILM peeling is done in the macular area in a circular manner in the vascular area.4. BSS injection is done through a 25/38 gauge cannula which is connected to a syringe containing BSS. These injections are done in 4 quadrants. The injection continues until the retinal bleb reaches the edge of the macular hole and can be seen exiting through the hole.5. Finally, air-fluid exchange is performed and internal tamponade is performed with the help of undiluted C3F8 gas in the amount of 0.4 ml inside the vitreous, and the patient is asked to sleep with face down position.</i_keyword>
      <i_keyword>Control group: Internal Limiting Membrane peeling and inverted flap . 1. Deep vitrectomy is performed.2. ILM staining is performed, ILM peeling is performed in the macular area in a circular manner in the vascular area.3. The removed ILM is placed as a flap inside the macular hole.4. Finally, air-fluid exchange is performed and internal tamponade is performed with the help of undiluted C3F8 gas, and the patient is asked to lie with face down position.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>What is the success rate of closing the anatomical macular hole (MH) with macular detachment (MD) based on Spectral domain Optical Coherence Tomography (SD-OCT)?. Timepoint: Before surgery and 1 and 3 months after surgery. Method of measurement: The degree of success in the anatomical closure of the macular hole is expressed by SD-OCT analysis.</prim_outcome>
      <prim_outcome>What is the success rate of anatomical closure of MH with Inverted Flap Of Internal Limiting Membrane Peeling  (i-ILM peeling) based on SD-OCT?. Timepoint: Before surgery and 1 and 3 months after surgery. Method of measurement: The degree of success in the anatomical closure of the macular hole is expressed by SD-OCT analysis.</prim_outcome>
      <prim_outcome>What is the level of visual acuity before and after MH surgery using the MD method with the help of Snellen chart and in the form of Logarithm of Minimum Angle of Resolution (LogMAR)?. Timepoint: Before surgery and 1 and 3 months after surgery. Method of measurement: Visual acuity is measured with the help of Snellen chart and is expressed based on Logarithm of Minimum Angle of Resolution (LogMAR).</prim_outcome>
      <prim_outcome>What is the level of visual acuity before and after MH surgery using the i-ILM peeling method with the help of Snellen chart and LogMAR?. Timepoint: Before surgery and 1 and 3 months after surgery. Method of measurement: Visual acuity is measured with the help of Snellen chart and is expressed based on Logarithm of Minimum Angle of Resolution (LogMAR).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-23</approval_date>
        <contact_name>Isafahan University of Medical Sciences</contact_name>
        <contact_address>MUI, Hezarjarib St Esfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
